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Abstract 
 
Long-term effectiveness and repeated administration of botulinum toxin A are the basis for its 
use in both neuromuscular disorders and certain painful conditions. Botulinum toxin A has 
been recently approved for migraine treatment, and its off-label use extends to other 
craniofacial pain disorders. However, recently it was reported that, after repeated injection, 
botulinum toxin loses its antinociceptive efficacy in rats. In present study with a similar 
design we compared the effects of single and repeated injections of botulinum toxin in 
formalin-induced orofacial pain. No statistically significant differences were found between 
single or repeatedly treated animal groups. Our results are in line with clinical experience and 
suggest that botulinum toxin can be re-administered in orofacial pain treatment. 
 
1. Introduction  
Botulinum toxin A (BTX-A) is used in neuromuscular and autonomous disorders 
characterized by cholinergic hyperactivity, and in treatment of some forms of pain (Jankovic 
et al., 2004; Jabbari and Machado, 2011). Important for its clinical application is the long-
term effectiveness and repeated use (Naumann et al., 2006). Apart from its off-label use in 
various painful conditions such as peripheral neuropathies, low back pain or various types of 
headache (Allam et al., 2005; Dodick et al., 2005; Foster et al., 2001; Jabbari and Machado, 
2011). BTX-A has been recently approved for chronic migraine treatment (Dodick et al., 
2010). 
In experimental animals it has been shown that BTX-A exhibits long-term reduction of 
inflammatory acute pain, neuropathic pain, visceral and deep somatic pain (Cui et al, 2004; 
Bach-Rojecky and Lackovic, 2005; Bach-Rojecky et al., 2005; Chuang et al., 2004; Krug et 
al., 2009). 
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In a recent report its effectiveness was demonstrated in orofacial formalin pain 8 days after 
the BTX-A pretreatment. However, when toxin was re-administered 42 days after the first 
treatment, the effect of BTX-A was not reproduced (Piovesan et al., 2011). Mentioned report 
that BTX-A loses its analgesic effect upon repeated injection in experimental animals is 
potentially very important for its clinical use in migraine and in some other chronic pain 
conditions, where repeated use is of high importance (Naumann et al., 2006). 
Aim of this study was to compare the effects of single or repeated injections of BTX-A in 
formalin-induced orofacial pain. In present study we did not find the difference between 
single and repeated injections of BTX-A.   
 
2. Materials and methods 
2.1 Animals 
Adult male Wistar rats (University of Zagreb School of Medicine, Croatia) weighing 300 g at 
the beginning of experiment were used. Animals were kept in 12 h/ 12 h light and dark cycle, 
with unlimited access to food and water.  Experiment was conducted according to the 
European Communities Council Directive (86/609/EEC) and recommendations of the 
International Association for the Study of Pain (Zimmerman, 1983). Animal procedures were 
approved by the Ethical Committee of University of Zagreb School of Medicine (permit No. 
07-76/2005-43).  
 
2.2 Drugs 
Botulinum toxin type A (Botox®, Allergan Inc., Irvine, CA, USA) was dissolved in 0.9% 
NaCl.  5 U/kg dose was administered unilaterally as 20 µl bolus into the whisker pad tissue 
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using a 27 1/2 gauge needle. 20 µl 0.9% saline solution was injected to control rats. Facial 
formalin injection was carried out using 50 µl of saline-diluted 2.5% formalin (Kemika, 
Zagreb, Croatia).  
 
2.3 Treatment and behavioral testing  
Three months old adult rats were divided into three groups, each consisting of five to six 
animals. First group of six conscious rats was injected with BTX-A into the left whisker pad 
tissue, while other two groups were left untreated. After 42 days, first group of rats underwent 
their second treatment of BTX-A, while the second and third group were injected with BTX-
A and saline, respectively. Period of 42 days between the two BTX-A injections was chosen 
based on study of Piovesan et al. (2011). 
After a period of six days, orofacial formalin test was performed to assess the antinociceptive 
activity of BTX-A. Animals were placed inside transparent chambers for 10-minute 
acclimatization period. Following the acclimatization, conscious, restrained rats were injected 
with formalin into the whisker pad ipsilateral to BTX-A pretreatment and immediately 
returned to the transparent chamber for a 45-minute observation period. Observers were blind 
to the animal treatment. Observation period was divided into 15 blocks of 3 minutes, and the 
number of seconds the animal spent in ipsilateral face rubbing or grooming was measured 
during phase I (0-12 min.) and phase II (12-45 min.) of formalin-induced pain (Raboisson and 
Dallel, 2004)..  
 
2.4 Statistical analysis 
Data were represented as mean +- SEM, and analyzed by one-way ANOVA followed by 
Tukey's HSD test (p<0.05).   
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3. Results 
 
Injection of BTX-A into whisker pad resulted in reduced movement of ipsilateral whiskers 
and their backward direction (Figure 1). In group receiving two injections of BTX-A no 
visible reduction of whisker movement was visible 42 days after the first treatment (prior to 
second BTX-A injection). Whisker paralysis after second BTX-A injection occurred again, as 
proof of efficiency of re-administered BTX-A (Figure 1C).  
In orofacial formalin test, phase I of rubbing/ grooming behavior was not affected by BTX-A 
treatment, while phase II in both BTX-A treated groups revealed significant reduction in 
number of seconds spent rubbing/grooming, in comparison with control (Figure 2). There was 
no statistically significant difference in time of facial grooming between the animals 
administered once or twice with BTX-A (Figure 2). 
 
4. Discussion 
According to experimental results recently published by Piovesan et al. (2011), BTX-A 
injections 8 days before formalin test inhibit orofacial pain. However, repeated treatment after 
42 days had no effect. This observation could have far reaching clinical consequences because 
it questions the usefulness of repeated injections of BTX-A in pain conditions. Basically, it is 
also intriguing because it might suggest that, after single injection, BTX-A makes permanent 
functional changes. Such putative changes might be connected either with mechanism of its 
uptake by peripheral sensory nerves mediated by SV2 proteins (Mahrhold et al., 2006), or 
with the mechanism of antinociceptive action, which is connected with axonal transport from 
periphery to central sensory nuclei, and likely with central SNAP-25 cleavage (Bach-Rojecky 
et al., 2009, Matak et al., 2011, Filipović et al., 2012). It might also suggest immunoresistence 
to BTX-A or possibly yet unknown long-term effect on synaptic plasticity caused by BTX-A. 
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However, in contrary to results from Piovesan et al. (2011), both single and repeated injection 
of BTX-A were equally effective in our study, which is in line with clinical experience in pain 
treatment. It also suggests that BTX-A does not induce permanent functional changes which 
could lead to ineffectiveness of repeated injection. Presence of ipsilateral whisker paralysis 
after second injection of BTX-A verifies that no immune resistance towards BTX-A occurred 
and the second bolus showed equal effectiveness on neuromuscular junction as in animals that 
were injected only once, which is in agreement with repeated clinical use in muscular 
disorders (Naumann et al., 2006).  
There are few basic differences between the two studies performed. Adult rats of the same age 
were used in our experiment, whereas the animals used in study from Piovesan et al. (2011) 
were juvenile when treated with BTX-A and tested with formalin for the first time. In the 
aforementioned study, formalin was applied twice to the same experimental animals. Cellular 
protein precipitation and possible permanent peripheral nerve ending damage in rats treated 
with formalin upon the first nociceptive testing might have interfered with second nociceptive 
testing or BTX-A uptake into the sensory neurons after second injection. Therefore, in our 
study the formalin test was conducted only once in all experimental groups. As described in 
previous literature phase I of the formalin test, caused by direct stimulation of nerve endings 
with formalin, is measured for the first 12 minutes of the test, while phase II represents central 
sensitization induced by peripheral nerve activity and is measured for the next 33 minutes 
(12-45 min) (Raboisson and Dallel, 2004). In our experiments, formalin-induced pain was 
measured during the whole period of 45 min while Piovesan et al. (2011) measured pain for 
30 minutes only.  
Our results did not confirm recent preclinical study from Piovesan et al. (2011), and suggest 
that BTX-A can be re-administered in orofacial pain and probably in BTX-A treatment of 
other forms of pain.  
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FIGURE LEGENDS 
Figure 1 Whisker appearance 1 day after administration of A) physiological saline, B) BTX
first injection, C) BTX-A second injection. Saline and BTX
whisker pad.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-A were administered to the left 
10 
 
-A 
  
 
 
 
Figure 2 Repeated BTX- A reduces 
whisker pad. Animals were pretreated into ipsilateral whisker pad one time or two times with 
5 U/kg BTX-A (42 days period between the two injections). Nociceptive testing was 
performed 6 days following the single or second, repeated injection of BTX
represented as mean+-SEM, * 
 
 
 
orofacial pain induced by 2.5% formalin injection into the 
- p<0.05 (Tukey's HSD test). 
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